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Background: Transcatheter Aortic Valve Implantation (TAVI) is an alternative treatment option for patients with aortic stenosis (AS) deemed high 
risk or unsuitable for aortic valve replacement. We introduced TAVI with a multidisciplinary team (MDT) approach including cardiologists, cardiac 
surgeons, imaging specialists, specialist nurse and anaesthetists and report about the results.
Methods: All patients referred for TAVI were assessed by the MDT. A team decision about the best procedural approaches (TF/TA) was based 
on which of the procedures potentially predicting best results.  As a result a total of 144 patients (mean age 82.6±7.32 years) with severe AS 
underwent TAVI with the Edwards Lifesciences Sapien™ bioprosthesis using TA (n=80; 56%) or TF (n=64; 44%) from August 2007 to September 2009 
at our institution. The mean ejection fraction was 49.8±11.4%, with maximum trans-aortic gradient of 79.4±23.8mmHg, mean gradient 48.9±15.3 
mmHg and mean aortic valve orifice area 0.6±0.16cm2. All patients were high risk based on logistic Euroscore (21.7±12.1%) with 70% of patients 
in NYHA class III/IV.
Results: All procedures were performed under general anaesthesia (n=139) or epidural (n=5). Procedural success was achieved in 98%. At 
discharge the echocardiographic mean trans-aortic gradient had fallen from 48.4±1.4 mmHg to 5.3±0.3mmHg, p<0.005; peak gradient from 
79±2.2 mmHg to 10.6±0.5 mmHg, p<0.005 Postoperative complications included stroke (7.6%), complete AV-block (4.9%), renal failure requiring 
haemofiltration (8.4%) and vascular injury (9%). The logistic Euroscore predicted operative mortality of 21.7±12.1% compared to actual outcomes 
of 9%. The Logistic Euroscore was a good predictor of short term mortality (logistic regression model, p<0.05). 30 days mortality post-TAVI for 
patients with logistic EuroSCORE <20%, 20-40% and >40% was 5.8%, 10.6 and 22%, respectively.
Conclusions: TAVI is a feasible treatment option in this patient group with promising short/medium-term results.  Careful case selection through 
a MDT approach appears to be the key for successful outcome. However, there is a patient group with very high Euroscores, which benefits less from 
an intervention.
